Measles Exposure Warning at Philadelphia International Airport

https://icaro.icaromediagroup.com/system/images/photos/16241004/original/open-uri20240603-56-1dlz5qv?1717449795
ICARO Media Group
News
03/06/2024 21h11

The exposure is believed to have occurred on Friday, May 31, 2024, between 2:50 p.m. and 6 p.m. in the Federal Inspection Area of Terminal A West.

According to officials, a person with measles passed through the airport during this time. It is important to note that this case is not related to a recent measles incident reported in Philadelphia. Dr. Landrus Burress, Director of the Division of Disease Control, stated that there is no immediate threat to the general public associated with this particular measles case.

However, the health department is urging individuals who may have been exposed to take precautionary measures if they are not protected against measles. The department emphasizes that several countries, including popular travel destinations, are currently experiencing measles outbreaks, increasing the potential for travel-related cases and subsequent outbreaks in the United States.

To ensure protection against measles, it is strongly advised that parents adhere to the immunization schedule recommended by the Centers for Disease Control and Prevention (CDC) and ensure their children are fully vaccinated at the earliest opportunity. Individuals planning to travel abroad should consult with their healthcare provider for information on necessary vaccinations.

Measles is a highly contagious virus that can be transmitted through direct contact with respiratory droplets or through airborne droplets from coughing and sneezing. Early symptoms include fever, runny nose, cough, and red, puffy eyes, followed by a characteristic rash. Measles can lead to serious complications such as pneumonia, brain infection, and, in severe cases, death.

The most effective protection against measles is the Measles, Mumps, and Rubella (MMR) vaccine. Health experts confirm the safety and high efficacy of the vaccine in preventing the virus. The MMR vaccine is recommended for individuals between 12-15 months of age, with a second dose administered between 4 and 6 years old. Infants under 12 months of age are not routinely eligible for vaccination and are therefore not protected. However, it is suggested that infants between 6 and 11 months old receive a dose of the MMR vaccine before traveling internationally.

Families traveling outside the United States should consult their pediatrician at least two weeks before departure to discuss vaccination requirements for infants.

For those who may have been exposed to measles, the Philadelphia Health Department provides the following recommendations:

1. Check your vaccination records or consult your healthcare provider to determine if you are protected against measles.
2. If you are protected, no further action is required.
3. If you are not protected, it is advised to receive a dose of the MMR vaccine and seek guidance from your healthcare provider on how to obtain it.
4. Individuals under 12 months of age, pregnant women who are not immune, or those with weakened immune systems should consult their healthcare provider immediately.
5. Measles is contagious four days before and four days after the appearance of the rash. If you may have been exposed and are not immune, wearing a mask in indoor public spaces and around unvaccinated individuals is recommended until three weeks after the exposure.
6. If you develop symptoms resembling measles through June 21, 2024, such as fever, runny nose, cough, puffy and red eyes, followed by a rash, contact your doctor immediately. Notify the Philadelphia Health Department at 215-685-6740 or the state health department at 877-724-3258.

Stay informed about measles and its prevention by visiting the provided link.

As the health department continues to investigate and monitor the situation, it is crucial for individuals to take appropriate measures to protect themselves and prevent further spread of the virus.

The views expressed in this article do not reflect the opinion of ICARO, or any of its affiliates.

Related